Regeneron reported a strong quarter for Dupixent as label expansions and ongoing demand fueled sales growth, lifting global Dupixent revenue to $6 billion for the first time in a quarter. The company cited continued robust demand across approved indications and said growth could moderate in the second half as launches annualize and prior-year comparisons tighten. Regeneron also highlighted a productive early discussion with Sanofi on broadening the collaboration, with executives referencing the potential to expand the partnership into additional assets aligned to the Dupixent portfolio.